Bridgeway Capital Management’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-22,000
Closed -$1.79M – 1304
2026
Q2
$1.79M Hold
22,000
– – 0.03% 602
2026
Q1
$1.5M Sell
22,000
-6,100
-22% -$432K 0.03% 608
2025
Q4
$2.13M Sell
28,100
-13,700
-33% -$996K 0.04% 514
2025
Q3
$2.57M Buy
+41,800
New +$2.18M 0.05% 471
2016
Q2
– Sell
-85,800
Closed -$553K – 1471
2016
Q1
$553K Buy
+85,800
New +$1.49M 0.01% 1000

Other funds holding PTCT

Bridgeway Capital Management's PTCT Position: Q3 2026 in Review

Bridgeway Capital Management sold out of PTC Therapeutics (PTCT) in Q3 2026, closing a stake of 22,000 shares — an estimated $1.79M sold.

Bridgeway Capital Management first reported a position in PTCT in Q1 2016 and held it in 5 quarters. The position peaked at $2.57M in Q3 2025. 360 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • Bridgeway Capital Management reported no remaining PTC Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Bridgeway Capital Management sold 22,000 PTC Therapeutics shares in Q3 2026, an estimated $1.79M.
  • Bridgeway Capital Management first reported a position in PTC Therapeutics in Q1 2016 and held it in 5 quarters.
  • Bridgeway Capital Management's PTC Therapeutics position peaked at $2.57M in Q3 2025.
  • 360 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.